"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
- Clinician Information:
Urobiotic Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Urobiotic-250 (oxytetracycline, sulfamethizole and phenazopyridine) is a combination antibiotic, sulfonamide, and analgesic used to treat genitourinary infections caused by susceptible organisms. These infections include the following: pyelonephritis, pyelitis, ureteritis, cystitis, prostatitis, and urethritis. Common side effects include nausea, diarrhea, vaginitis, dermatitis, allergic reactions, and swelling of the tongue, mouth, or rectum.
A dose of 1 capsule of Urobiotic-250 four times daily is suggested. Urobiotic-250 may interact with other drugs. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before starting treatment with Urobiotic-250. Consult your doctor before breastfeeding.
Our Urobiotic-250 (oxytetracycline, sulfamethizole and phenazopyridine) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Urobiotic FDA Prescribing Information: Side Effects
Glossitis, stomatitis, proctitis, nausea, diarrhea, vaginitis, and dermatitis, as well as reactions of an allergic nature, may occur during oxytetracycline HCl therapy, but are rare. If adverse reactions, individual idiosyncrasy, or allergy occur, discontinue medication. Rare instances of esophagitis and esophageal ulcerations have been reported in patients receiving capsule forms of drugs in the tetracycline class. Most of these patients took medications immediately before going to bed. (See DOSAGE AND ADMINISTRATION.)
With oxytetracycline therapy bulging fontanels in infants and benign intracranial hypertension in adults have been reported in individuals receiving full therapeutic dosages. These conditions disappeared rapidly when the drug was discontinued.
As in all sulfonamide therapy, the following reactions may occur: nausea, vomiting, diarrhea, hepatitis, pancreatitis, blood dyscrasias, neuropathy, drug fever, skin rash, injection of the conjunctiva and sclera, petechiae, purpura, hematuria and crystalluria. The dosage should be decreased or the drug withdrawn, depending upon the severity of the reaction.
Read the entire FDA prescribing information for Urobiotic (Oxytetracycline, Sulfamethizole and Phenazopyridine) »
Additional Urobiotic Information
Report Problems to the Food and Drug Administration
Find out what women really need.